Dr. Alexander M. Merson

Daniel Sagalovich is an Oncologist and an Urologist in Staten Island, New York. Dr. Sagalovich is rated as an Advanced provider by MediFind in the treatment of Boils. His top areas of expertise are Renal Cell Carcinoma (RCC), Obstructive Uropathy, Ureterocele, Nephrectomy, and Ureteroscopy.

Michael J. Schwartz, MD, is Chief of Urology at Long Island Jewish Medical Center and Director of Urology Services for Northwell Health's Central Region. Dr. Schwartz specializes in minimally invasive procedures to treat prostate cancer. He has vast experience in robotic-assisted radical prostatectomy, evolving surgical techniques over time to minimize treatment-related side effects. For qualifying prostate cancer patients, Dr. Schwartz also offers focal ablation therapies, using sophisticated image guidance and focal tissue ablation to eradicate prostate cancer with few side effects. He has additional expertise in urologic oncology and surgery to treat kidney, bladder, adrenal and testicular cancers. Becoming a doctor always felt natural to me, Dr. Schwartz says. I was always interested in helping others, and urology is a wonderful blend of both medical and surgical care, allowing for the development of long-term relationships with my patients. Dr. Schwartz earned his medical degree from Warren Alpert Medical School of Brown University and pursued his residency training in urology at New York-Presbyterian Hospital, Cornell. He received his fellowship training in advanced laparoscopic and endoscopic surgery at North Shore University Hospital and Long Island Jewish Medical Center. Dr. Schwartz values a team-based approach to care, working with radiologists, pathologists and medical oncologists to create individualized, evidence-based treatment plans. He also carefully listens to patients to meet their unique goals and preferences. In addition to treating prostate cancer, Dr. Schwartz is a pioneer in prostate cancer diagnosis. He was an early adopter of transperineal biopsy-which eliminates the infection risk associated with the prior transrectal method-and helped the Smith Institute of Urology transition to using that approach for all patients requiring prostate biopsy across Northwell Health. His research focuses on both diagnostics and treatment of prostate cancer, and he is involved with several clinical trials for focal therapy. He is a member of the American Urological Association and Society of Urologic Oncology. He is Associate Professor of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. For Dr. Schwartz, one of the best parts of his job is getting to know his patients. I have the privilege of seeing their humanity, learning about their lives and discovering what's important to them, he says. Their experiences inspire me every day. Dr. Schwartz is rated as an Advanced provider by MediFind in the treatment of Boils. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Enlarged Prostate (BPH), Reconstructive Urology Surgery, and Nephrectomy.

Dr. Simon J Hall MD is a board certified urologist with Fellowship training in Urologic Oncology. His clinical interests include the diagnosis and treatment of Prostate, Bladder and Kidney cancers. He is especially interested in Active Surveillance of men with prostate cancer and men and women with incidentally found small renal masses and the creation of continent urinary reconstructions for patients who need to undergo cystectomy for Bladder cancer. Furthermore, Dr. Hall has a keen interest in treating patients with recurrent prostate cancer following definitive therapy. He believes that objective & balanced communication with the patient and family is the key to decision making and individualized care. Over the years Dr. Hall has been named as Best Doctor, both nationally and regionally, by organizations such as Castle Connolly, SuperDoctors and New York Magazine. Dr. Hall s research has focused of new therapies for prostate and bladder cancer; he has participated in numerous clinical trials, some of which generated data resulting in FDA approval of Sipleucel-T (Provenge) and enzulutamide (Xtandi). He oversees a laboratory investigating novel approaches to negating the Androgen Receptor, an important key driver of castration resistant prostate cancer. Decision making and improved methods of clinical care for patients with bladder and prostate cancer are important aspects of his research interests in collaboration with Dr. Michael Diefenbach, a behavioral scientist in the Departments of Urology & Medicine at NS-LIJ. He has authored or co-authored nearly 70 peer reviewed articles in Journals such as Journal of Urology, Urology, British Journal of Urology, Clinical Cancer Research and Science. Dr. Hall received his MD from the College of Physicians & Surgeons of Columbia University. He then completed two years of Surgery training at the Mount Sinai Medical Center followed by a four year residency in Urology at Boston University School of Medicine. This was followed by a 2 year fellowship in Urologic Oncology in the Scott Department of Urology at Baylor College of Medicine. Prior to joining the Smith Institute for Urology, he served on the faculty of Icahn School of Medicine at Mount Sinai for 18 years, holding various positions including Kyung Hyun Kim MD Chair of Urology and the Director of the Deane Prostate Health & Research Center. Dr. Hall is rated as a Distinguished provider by MediFind in the treatment of Boils. His top areas of expertise are Muscle Invasive Bladder Cancer, Prostate Cancer, Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.